Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Invest
Главные авторы: Ramos, Carlos A., Ballard, Brandon, Zhang, Huimin, Dakhova, Olga, Gee, Adrian P., Mei, Zhuyong, Bilgi, Mrinalini, Wu, Meng-Fen, Liu, Hao, Grilley, Bambi, Bollard, Catherine M., Chang, Bill H., Rooney, Cliona M., Brenner, Malcolm K., Heslop, Helen E., Dotti, Gianpietro, Savoldo, Barbara
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Clinical Investigation 2017
Предметы:
Clinical Medicine
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5669573/
https://ncbi.nlm.nih.gov/pubmed/28805662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI94306
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы